The effect of ticagrelor on growth of small abdominal aortic aneurysms—a randomized controlled trial

Wanhainen, Anders; Mani, Kevin; Kullberg, Joel; Svensjö, Sverker; Bersztel, Adam; Karlsson, Lars; Holst, Jan; Gottsäter, Anders; Linné, Anneli; Gillgren, Peter; Langenskiöld, Marcus; Hultgren, Rebecka; Roy, Joy; Gilgen, Nils Peter; Åhlström, Håkan; Lederle, Frank A.; Björck, Martin

doi:10.1093/cvr/cvz133

Cited by 39 publications

(55 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of a P2Y12 receptor inhibitor as ticagrelor treatment revealed a lack of difference in AAA size compared to placebo-treated subjects, suggesting that ticagrelor has no effect on the development of small AAAs. However, in this study, most of the patients did not present an ILT (213). These results have been summarized in Table 4 and Figure 3.…”

Section: Platelets Participate To the Development Of The Abdominal Aocontrasting

confidence: 59%

Platelets Are at the Nexus of Vascular Diseases

Lebas

Yahiaoui

Martos

et al. 2019

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Platelets are important actors of cardiovascular diseases (CVD). Current antiplatelet drugs that inhibit platelet aggregation have been shown to be effective in CVD treatment. However, the management of bleeding complications is still an issue in vascular diseases. While platelets can act individually, they interact with vascular cells and leukocytes at sites of vascular injury and inflammation. The main goal remains to better understand platelet mechanisms in thrombo-inflammatory diseases and provide new lines of safe treatments. Beyond their role in hemostasis and thrombosis, recent studies have reported the role of several aspects of platelet functions in CVD progression. In this review, we will provide a comprehensive overview of platelet mechanisms involved in several vascular diseases.

show abstract

Section: Platelets Participate To the Development Of The Abdominal Aocontrasting

confidence: 59%

Platelets Are at the Nexus of Vascular Diseases

Lebas

Yahiaoui

Martos

et al. 2019

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…The TicAAA study, randomized 144 patients with AAA to receive either ticagrelor 90 mg twice daily or placebo. 27 After 12 months, the AAA volume growth rate assessed by MRI did not differ between the ticagrelor and the placebo groups (9.1% vs. 7.5% , P = 0.205). Neither the AAA diameter nor the intraluminal thrombus volume change differed between treatment groups.…”

Section: Clinical Trialsmentioning

confidence: 82%

Progress in aorta and peripheral cardiovascular disease research

Mazzolai¹,

Alatri²,

Rivière

et al. 2021

Cardiovascular Research

View full text Add to dashboard Cite

Although coronavirus disease 2019 seems to be the leading topic in research number of outstanding studies have been published in the field of aorta and peripheral vascular diseases likely affecting our clinical practice in the near future. This review article highlights key research on vascular diseases published in 2020. Some studies have shed light in the pathophysiology of aortic aneurysm and dissection suggesting a potential role for kinase inhibitors as new therapeutic options. A first proteogenomic study on fibromuscular dysplasia (FMD) revealed a promising novel disease gene and provided proof-of-concept for a protein/lipid-based FMD blood test. The role of NADPH oxidases in vascular physiology, and particularly endothelial cell differentiation, is highlighted with potential for cell therapy development. Imaging of vulnerable plaque has been an intense field of research. Features of plaque vulnerability on magnetic resonance imaging as an under-recognized cause of stroke are discussed. Major clinical trials on lower extremity peripheral artery disease have shown added benefit of dual antithrombotic (aspirin plus rivaroxaban) treatment.

show abstract

“…For example, in this study shear stress was more markedly decreased in the aneurysm sac for progressing AAA (21-mL growth) compared with stable AAA (3-mL growth), with most (80%) of that progression because of ILT growth. Elucidating such influences might, for example, contribute to our understanding of the failure of platelet inhibitors to modulate AAA growth (10).…”

mentioning

confidence: 99%

“…Second, the study highlights that because of the rarity of rupture (,0.4% per year in men under surveillance), assessment of new risk stratification markers (and therapies [10]) are often limited to studying their association with progression during short intervals. Validating predictive model accuracy over a fixed time interval is in line with the increasing appreciation of both discontinuous growth of AAA and the temporal evolution of the many factors that we believe affect progression.…”

mentioning

confidence: 99%